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SUMMARY – The anemia of chronic disease (ACD) is the most prevalent anemia after iron 
deficiency anemia. It is associated with infectious, inflammatory and neoplastic disease. ACD is 
a medical condition caused by the release of cytokines which mediate inflammatory and immune 
response (tumor necrosis factor, interleukins 1 and 6, and interferon). Abnormal iron metabolism 
with iron trapping in reticuloendothelial cells is primarily the cause of this condition, making iron 
unavailable for erythropoiesis although iron tissue reserves are elevated. Disorder in erythropoietin 
secretion and shortening of red cell life span also play a role in the pathogenesis of ACD. The main 
therapy is treatment of the underlying disorder and red cell transfusions in severe anemia. In more 
severe (protracted) anemias that lead to impaired quality of life and have an impact on the mortality 
and survival rate, erythropoiesis stimulating agents are used. Recently, new possibilities are being 
evaluated in terms of therapy for ACD in defined conditions, such as chelating agents, as well as 
hepcidin antagonist and other erythropoiesis stimulating agents.
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Introduction 
The anemia of chronic disease (ACD) is a result of 
body response to inflammatory or system disease1. It 
was first described in 1930 and thoroughly described 
in 1950 by Wintrobe and Cartwright2. ACD, usu-
ally a mild to moderate anemia, is the most preva-
lent anemia after iron deficiency anemia and also the 
most prevalent anemia in hospitalized patients. This 
anemia, first described in chronic infections, may 
be found in subjects with diseases involving acute or 
chronic immune activation and thus could be seen in 
a variety of inflammatory conditions, acute or chronic 
infections, rheumatologic disorders, autoimmune dis-
orders and cancer3. Most patients with ACD do have 
active infections, inflammatory conditions, or malig-
nancy. In severe acute infection and sepsis, ACD can 
develop within few days4. Not only fever associated 
with infections has been shown to inhibit bacterial 
growth, but decreased iron concentrations (as seen 
in ACD) act synergistically with pyrexia to inhibit 
bacterial growth. Thus, attempt by hosts to withhold 
iron from the invaders has been termed ‘nutritional 
immunity’ and has been postulated to be an adap-
tive factor of ACD in infections. In malignant dis-
ease, the incidence of ACD can be as high as 70%, 
and even higher in patients treated with radiotherapy 
and chemotherapy5. Also, ACD can also be seen in 
severe trauma, alcoholic liver disease, congestive heart 
failure, thrombosis, chronic pulmonary disease, dia-
betes, or can be associated with a variety of medical 
problems. Besides other factors, age also influences 
the development of ACD.
It is considered that many factors have a role in the 
pathogenesis of ACD but it is still not fully understood. 
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The multifactorial etiology of ACD involves not only 
block in iron reutilization by red blood cells (RBC) 
but also a decreased RBC lifespan, direct inhibition 
of hematopoiesis, and relative deficiency of erythro-
poietin. The severity and grade of ACD are related to 
the stage of underlying condition. Many studies have 
shown that the grade of anemia associated with un-
derlying disease is an important prognostic factor, but 
it has not been elucidated whether treatment of ACD 
contributes to better prognosis6. ACD is characterized 
by decreased serum iron, decreased total iron-binding 
capacity and increased iron stores. Reduced level of 
plasma iron is the main laboratory finding in ACD. 
Therefore, differentiating between ACD and iron de-
ficiency anemia can be diagnostically challenging. In 
both conditions, iron plasma level is reduced. How-
ever, in iron deficiency anemia, iron deficit is absolute, 
whereas in ACD it is functional and characterized by 
macrophage iron retention induced by cytokines and 
the master regulator hepcidin7. Thus, in ACD, iron 
body reserves are increased, but iron is unavailable for 
hemoglobin synthesis due to the increased reuptake of 
iron within reticuloendothelial cells (which are iron 
reservoir in human body). The increased release of 
cytokines, such as interleukin(IL)-1, IL-6, tumor ne-
crosis factor (TNF)-alpha and transforming growth 
factor (TGF)-beta, which is indirectly mediated via 
interferon (IFN) alpha, beta and gamma, results in 
abnormal iron metabolism that is the central distur-
bance in the pathogenesis of ACD8,9. Also, expression 
of the liver-derived acute phase protein hepcidin, the 
key regulator of iron homeostasis, is induced by both 
iron overload and inflammatory stimuli. Hepcidin 
binds to ferroportin, the only known iron export pro-
tein, resulting in the internalization and degradation 
of this transporter, which then blocks iron export from 
enterocytes and macrophages to the circulation10.
The aim of this article is to present new insights in 
the ACD pathogenesis, treatment options and treat-
ment issues.
The Pathogenesis of ACD
Anemia of chronic disease is anemia connected 
with inflammation or system disease. It is mediated 
by inflammatory cytokines TNF, IL-1, IL-6 and 
IFN. Studies on humoral mediators have shown an 
increased concentration of inflammatory cytokines in 
chronic diseases and their relation with ACD. Proin-
flammatory cytokine activity contributes to iron me-
tabolism dysregulation, decreased RBC production in 
bone marrow, shortening the RBC lifespan, and de-
creased erythropoietin secretion1. This multifactorial 
etiology of ACD associated with inflammatory cy-
tokines is present in underlying diseases and the most 
frequent causes and prevalence of ACD are listed in 
Table 13.
Cytokine activity on disturbance in iron metabo-
lism is the main feature of ACD. Iron plasma level 
is decreased, while the level of iron in the reticu-
loendothelial system is increased. Reduced availabil-
ity of iron leads to restricted iron in erythropoiesis. 
Additionally, inflammatory cytokines stimulate iron 
storage into macrophages in multiple ways: stimulat-
ing receptors for erythrophagocytosis, stimulating 
expression of the protein divalent metal transporter 
(DMT-1) through which the transmembrane import 
of non-transferrin iron and inducing transferrin re-
ceptor (TfR) iron uptake in macrophages occur. The 
increased iron storage in macrophages and hepato-
cytes leads to increased ferritin expression8,9.
Disturbance in iron metabolism can be explained 
by hepcidin activity. Hepcidin is a peptide synthesized 
in the liver. Normally, hepcidin synthesis is increased 
in iron excess and decreased in anemia and hypoxia. 
It is a systemic regulator of iron transport from iron 
storage cells into plasma due to its inhibitory effect on 
iron release from cells, by degradation of ferroportin, 
which is the only iron export protein. In inflammatory 
state induced by IL-6, hepcidin synthesis is increased 
leading to decreased iron release from macrophages 
and other iron storage cell, thus causing plasma hy-
poferremia10,11.
The mechanism of decreased RBC half-life in 
ACD was not understood for a long time. It is consid-
ered that inflammatory cytokine IL-6 activates mac-
Table 1. Underlying causes of anemia of chronic disease3
Underlying disease Prevalence (%)
Infection (acute or chronic) 18-95
Neoplasm (hematologic or solid) 30-77
Autoimmune diseases 8-71
Chronic rejection after transplantation 8-70
Chronic kidney disease 23-50
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rophages and leads to RBC hemolysis. The mechanism 
of hemolysis is explained in increased erythrophago-
cytosis, which is the normal pathway for degradation 
of old RBC and reutilization of iron from heme11.
In ACD, the RBC production in bone marrow is 
impaired due to the inhibitory effects of TNF-alpha, 
beta and IL-1, which is indirectly mediated by IFN 
alpha, beta and gamma. The most potent inhibitory 
effect appears to be the one by IFN gamma. The 
mechanism involves induction of apoptosis or down-
regulation of the expression of erythropoietin recep-
tors or other hematopoietic growth factors. Acute 
phase proteins efficiently inhibit TfR and TfR medi-
ated iron uptake in erythroid precursors12,13. Also, in 
in vitro conditions, hepcidin has an inhibitory effect 
on the erythroid colony forming units14.
Serum erythropoietin level in ACD is inadequate 
for the degree of anemia, due to decreased renal pro-
duction mediated by inflammatory cytokines. Eryth-
ropoietin response in ACD appears to be more inad-
equate if the activity of the underlying disease is more 
severe and if the levels of plasma cytokines, especially 
IFN gamma and TNF alpha, are higher. The in-
hibitory cytokine effects on erythroid colony forming 
units can be partially prevented by increased levels of 
erythropoietin15.
Diagnosis of ACD (Laboratory Findings)
The diagnosis of ACD is based on exclusion and is 
often difficult. Various laboratory tests have been sug-
gested as helpful. The best way to diagnose ACD is to 
document anemia of underproduction (low reticulocyte 
index) with low serum iron and transferrin levels and 
elevated serum ferritin in a setting of systemic, usually 
inflammatory illness. Other causes of anemia (hemo-
lysis, nutritional deficiency, or sequestration) should be 
ruled out. A component of iron deficiency should be 
strongly considered in a patient with systemic inflam-
mation and low or ‘normal’ serum ferritin. Often those 
other causes of anemia accompany ACD.
The anemia of chronic disease is usually normo-
cytic and normochromic, and in some cases can be 
microcytic and hypochromic. Anemia is usually mild 
with hemoglobin concentration >100 g/L or moder-
ate with hemoglobin in the range of 85-100 g/L; he-
moglobin level of <85 g/L can only be found in some 
patients. 
Reticulocyte count is normal or low as well. De-
finitive diagnosis may be difficult to reach if there is 
coexisting blood loss, the effects of medication or he-
reditary defects of hematopoiesis such as thalassemia. 
Body iron status should be evaluated, so that iron de-
ficiency anemia can be ruled out. In ACD and iron 
deficiency anemia, serum concentration of iron and 
transferrin saturation (Fe/TIBC ratio) are reduced, 
which indicates hypoferremia due to higher storage 
in reticuloendothelial cells in the former and absolute 
iron deficiency in the latter (Table 2)15.
Ferritin as a marker of body iron reserves is a gen-
eral indicator of iron quantity in reversible reserves 
(stores). In iron deficiency anemia, ferritin level is 
lower than 30 ng/mL, whereas in ACD its level is 
normal or higher. The soluble transferrin receptors 
(sTfR) are fragments of membrane receptors that are 
increased when iron availability for erythropoiesis is 
low, which is the way how the body manifests iron 
deficiency. In ACD, the levels of sTfR are normal be-
cause inflammatory cytokines have negative effect on 
TfR expression. Some data indicate that sTfR offers 
Table 2. Serum levels differentiating anemia of chronic disease (ACD) from iron deficiency anemia and combined 
states15
Variable ACD Iron deficiency anemia Combined states
Iron Low Low Low
Transferrin Low or normal High Low
Transferrin saturation Low Low Low
Ferritin Normal or high Low Low or normal
Soluble transferrin receptors (sTFR) Normal High Normal or high
sTfR/log ferritin index Low (<1) High (>2) High (>2)
Cytokine levels High Normal High
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little advantage over conventional laboratory indica-
tors of iron status6 and might not assess iron status in 
ACD patients. The ratio of sTfR (nmol/L) concen-
tration and log of the ferritin level (µmol/L) (sTfR/
log ferritin index) may be helpful. A ratio less than 1 
suggest ACD, and ratio more than 2 ACD with co-
existing iron deficiency7,15,16. Bone marrow examina-
tion (cytochemistry) may also be helpful in differen-
tiating ACD and iron deficiency anemia. Assessment 
of bone marrow aspirate stained with Perls’ stain has 
been considered the gold standard for the diagnosis 
of iron deficiency anemia, but the results may vary 
greatly depending on the method of examination. In 
typical cases, extra-hemoglobin iron level is increased 
in ACD and decreased or absent in iron deficiency 
anemia. Bone marrow iron is almost never used for 
clinical decision in daily practice, and decisions are 
instead based only on peripheral iron indices17.
Treatment of ACD
Treatment of ACD is seldom needed. Correction 
of underlying condition or disease is therapy of choice 
for ACD. In most cases, termination of inflammatory 
process leads to correction of anemia. Blood transfu-
sion therapy is an option as quick therapy in severe 
anemia. Iron as therapy option in ACD is not effi-
cient, and may even be harmful because it is an essen-
tial nutrient for proliferating microorganisms as well 
as for tumor cells4,18,19. Patients with ACD and ab-
solute iron deficiency may receive iron supplementa-
tion. Reduced response to endogenous erythropoietin 
encouraged research into the usage of erythropoietin 
as a therapy option in ACD. In that case, recombinant 
human erythropoietin (rhEPO) is used for correction 
of anemia and its therapeutic effect has been shown in 
a large number of studies20,21. The level of endogenous 
erythropoietin does not correlate with the response to 
rhEPO therapy, although in patients with a reduced 
level of endogenous erythropoietin, rhEPO therapy 
may lead to better therapeutic response. The dos-
age of rhEPO for treatment of ACD is several times 
higher than that used for anemia in chronic kidney 
disease. ACD does not need correction in every case, 
but always requires correction in conditions where it 
affects the quality of life, e.g., in patients with cancer 
or where it affects lifelong prognosis, as in patients 
with heart failure or chronic renal failure20,21. Accord-
ing to guidelines, the target hemoglobin level is 110 to 
120 g/L because higher levels can be associated with 
higher mortality21.
New findings on ACD pathophysiology will pro-
vide a new therapeutic approach for these patients. It 
is considered that iron chelation therapy can induce 
endogenous formation of erythropoietin, and hepcidin 
antagonist may prevent the retention of iron within 
the reticuloendothelial system22-24. Moreover, iron ch-
elators such as deferoxamine have been shown in some 
studies to exert mild effect on ACD, perhaps also by 
decreasing free radicals and inflammation. New tests 
providing better distinction between the functional 
and absolute iron deficiency will enable better thera-
peutic regimen for ACD7.
Treatment Issues in ACD
The main question is whether ACD is neglected 
and underdiagnosed, and on the other hand, should 
we insist on treating mild or moderate ACD? 
There is a hypothesis suggesting that ACD is in 
fact a protective and adaptive mechanism of the hu-
man body as a response to the underlying disease and 
that treatment of mild and moderate anemia leads to 
higher mortality25. Under normal conditions, tissue 
oxygen supply is four times higher than the needs. 
Thus, in conditions of mild or moderate non-acute 
anemia, tissue is provided with an adequate amount 
of oxygen. 
In many underlying conditions such as in patients 
with cancer, heart failure or chronic renal failure, ane-
mia is associated with a higher mortality rate. How-
ever, the degree and severity of anemia only reflect the 
severity of the underlying disease.
A number of studies have identified anemia as an 
independent predictor of poor prognosis; however, in 
some studies, anemia was excluded as an independent 
prognostic factor if the variables such as C-reactive 
protein and the level of cytokines, which reflect the 
severity of inflammation were included9. In this case, 
if anemia is a marker of the underlying disease, thera-
py of anemia cannot improve the overall prognosis.
According to the hypothesis that anemia is an 
adaptive mechanism of the human body in response to 
the underlying disease, iron retention in macrophages 
is one of the mechanisms that limit the amount of iron 
available to microorganisms and cancer cells, as iron 
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is an essential nutrient for their growth4,19. A meta-
analysis of 51 randomized studies has shown higher 
mortality associated with the use of erythropoiesis-
stimulating agents (ESAs) in order to achieve normal 
hemoglobin level rate compared to lower hemoglobin 
level in patients with cancer21. Studies involved pa-
tients with neck and head tumors, non-small lung 
carcinomas and breast carcinoma. This result is at-
tributed to a higher rate of thromboembolic incidents 
in patients with a higher level of hemoglobin and to 
stimulation of tumor growth32.
If ACD is a protective mechanism, then attempts 
to treat it should have negative effects on the human 
body. This hypothesis has been supported in many 
studies that monitored the impact of RBC transfu-
sion or use of ESA26-30.
Two observational studies have proven that RBC 
transfusion can be a predictor of lethal outcome in 
critically ill patients (sepsis, congestive heart failure, 
severe pancreatitis) if administered under less rigorous 
conditions (Hb <100 g/L) than according to conserva-
tive criteria (Hb <70-80 g/L). Mortality rate was sig-
nificantly higher in the group of patients that received 
transfusion under less rigorous criteria compared with 
those that received transfusion under conservative cri-
teria (16.1% vs. 8.7%)27-31. A higher mortality rate due 
to the treatment of anemia was demonstrated in three 
observational studies in patients with acute coronary 
syndrome29.
According to a meta-analysis, the use of ESA has 
no benefit in terms of overall mortality rate in criti-
cally ill patients regardless of the reduced transfusion 
usage26-30. In patients with chronic renal insufficiency 
anemia, there are two important components: anemia 
due to erythropoietin deficiency and ACD. The use 
of ESA in the treatment of anemia in chronic kidney 
disease resulted in great benefit because the higher 
hemoglobin level decreased comorbidities and devel-
opment of system disease, thus reducing the compo-
nent of ACD. In these patients, the higher mortality 
rate (hazard ratio 1.10) due to the use of ESA, when a 
higher hemoglobin level has been attained, is in cor-
relation with the higher incidence of thromboembolic 
incidents (7.5% vs. 4.9%)31,32.
Currently, there are no published studies reporting 
the results of ACD treatment with ESA in patients 
with rheumatoid arthritis and inflammatory bowel 
disease, which would be very informative for the hy-
pothesis that anemia is an adaptive response and that 
if treated it may worsen rather than improve clinical 
outcome.
Conclusion
There has been progress in the understanding of 
the pathophysiology of ACD. This refers to new find-
ings in the understanding of iron homeostasis and 
its disturbances, particularly to the action of hepci-
din that binds to ferroportin resulting in iron block 
in macrophages. These new insights have contributed 
to the development of new recommendations for the 
treatment of ACD. As for now, treatment of ACD in-
cludes therapy for the underlying disease, RBC trans-
fusion, and in some cases erythropoietin usage. In the 
future, strategies could include the use of iron chela-
tor therapy, which induces endogenous erythropoietin 
synthesis; hepcidin antagonist which would prevent 
iron retention in the reticuloendothelial system; and 
inflammatory cytokine antagonists23,24. A recent hy-
pothesis and studies have raised the issues of the use-
fulness or harmfulness of ACD treatment, especially 
when it is mild or moderate.
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Sažetak
ANEMIJA KRONIčNE BOLESTI: BOLEST ILI ADAPTIVNI MEHANIZAM 
D. Županić-Krmek, M. Sučić i D. Bekić
Anemija kronične bolesti je iza sideropenične anemije najraširenija vrsta anemije. Pojavljuje se uz infekcije, upale i 
zloćudne bolesti. Nastaje kao posljedica lučenja upalnih citokina koji posreduju u upalnom i imunom odgovoru (faktor 
nekroze tumora, inteleukin-1 i interferoni). Glavni poremećaj se sastoji u poremećenom metabolizmu željeza koje ostaje 
zarobljeno u stanicama retikuloendotelnog sustava i nije na raspolaganju eritropoezi iako ga u tkivnim rezervama ima u 
suvišku. Također je poremećeno lučenje eritropoetina i skraćen je poluživot eritrocita. Liječenje se sastoji u terapiji osnovne 
bolesti, transfuzijama eritrocita kod teže anemije, a  kod dugotrajnih anemija koje ugrožavaju kavalitetu života i imaju 
utjecaj na ukupnu smrtnost i možda  preživljenje terapija se po određenim definiranim uvjetima može provoditi tvarima 
koje stimuliraju eritropoezu. U novije vrijeme se razmatraju i druge mogućnosti liječenja poput kelirajućih tvari.
Ključne riječi: Anemija – krv; Anemija – patofiziologija; Anemija – terapija; Kronična bolest; Upala
